Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Breast Cancer Research

Fig. 4

From: Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs

Fig. 4

Gemcitabine depletes MDSCs in the spleen and lungs of 4T1 tumor-bearing mice. a Number of CD11b+Gr1+ cells in the spleens of 4T1 tumor-bearing mice after a single dose of 60 mg/kg gemcitabine administered 17 days after tumor implant. b Number of CD11b+Gr1+ cells in the lungs of 4T1 tumor-bearing mice after a single dose of 60 mg/kg gemcitabine administered 17 days after tumor implant. c Spleen weights of 4T1 tumor-bearing mice after gemcitabine treatment. Data are mean ± SEM from 4 to 6 mice per group. Significance compared to time 0. d Fold change in metabolic activity of 4T1 tumor cells and MSC2 myeloid cells treated with increasing doses of gemcitabine in vitro. Data are mean ± SEM from 6 experimental repeats; curves are significantly different (p < 0.001) as tested by ANOVA

Back to article page